Medical Tourism Companies

Why Medical Tourism Is Expanding?

The Global Medical Tourism Market reached an estimated USD 58.25 billion in 2025 and is projected to accelerate to USD 292.87 billion by 2035, expanding at a CAGR of 18.2% over the 2025–2035 forecast period. This trajectory is anchored in a structural cost arbitrage: advanced medical procedures in India, Thailand, Malaysia, Mexico, Turkey, and the Philippines cost 50–80% less than in the United States, Canada, or Western Europe, even after accounting for travel, accommodation, and ancillary expenses.

The convergence of rising healthcare costs in developed nations, improved international connectivity, digital health platforms, and JCI-accredited hospital infrastructure has transformed cross-border healthcare from a niche alternative into a mainstream patient decision. Over 1.3 billion annual international tourist movements, per WHO global health datasets, provide the logistical backbone that supports cross-border healthcare accessibility at scale.

There’s a basic shift in demand in how people get access to care. Demand for outbound medical tourism is rising since CDC healthcare use data shows that more than 60% of U.S. people postpone or forgo treatment owing to excessive prices. The Cosmetic Surgery category is the largest treatment section, accounting for 28% of the treatment market share in 2024. Fertility is the fastest-growing treatment segment through 2035, due to demographic changes and rising reproductive tourism corridors.

In terms of service provider, private healthcare has a 72% share with best infrastructure, premium services and dedicated international patient management systems. North America generates over 45% of global revenue, driven by high domestic healthcare costs and demand for cross-border treatment. Asia-Pacific is the fastest expanding area, driven by Thailand’s wellness-integrated therapeutic approach and India’s cost-competitive surgical competence.

What Structurally Separates Leaders from the Field?

The MRFR’s category leadership is defined by four structural variables that segment the Medical Tourism Market: JCI accreditation and international quality certification depth that transforms patient skepticism into trust; geographic positioning near international airports and visa-friendly corridors that reduce friction for inbound patients; integrated wellness-to-therapeutic service bundles that extend average revenue per patient beyond the core procedure; and digital patient engagement platforms --- including telemedicine pre-consultation, AI-driven treatment matching, and post-operative remote monitoring --- that compress the entire care journey into a seamless cross-border experience. Hospitals that can offer a full ‘medical vacation’ ecosystem – integrating surgery, recovery, wellness and tourism, as well as cost savings – are taking a disproportionate part of the high-value foreign patient sector.

Top 10 Global Medical Tourism Companies --- MRFR Rankings (2026)

MRFR has identified and profiled the following leading medical tourism companies globally, evaluated on the basis of revenue performance, geographic presence, international patient volume, JCI accreditation status, service breadth, and digital patient engagement capabilities. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of June 2026.

Detailed Company Profiles

1. Bangkok Dusit Medical Services (BDMS) | SET: BDMS | Bangkok, Thailand

According to its SET filings, BDMS, the largest private healthcare provider in Thailand, reported consolidated operating income of THB 113,206 million (~USD 3.2 billion) in FY2023. The group’s hospital activities earned revenue of THB 107,514 million. International patient revenue increased 5% year-on-year and accounted for 28% of overall hospital revenue. BDMS runs a multi-brand network of hospitals including Bangkok Hospital, Samitivej, Phyathai and Paolo Hospital, with plans to expand to Chiangmai, Khao Yai and Chonburi.

For 2025, network additions include Samitivej International Children’s Hospital (103 beds), Bangkok Hospital Chiangmai (90 beds), and Phyathai Bowin Hospital (59 beds), demonstrating controlled capacity increase in conjunction with medical tourism corridor development. The strategic moat for BDMS is its scale-driven cost structure and breadth of brand portfolio. No rival in Southeast Asia has the same level of combined bed count, specialist density, and international patient service infrastructure.

2. Bumrungrad International Hospital | SET: BH | Bangkok, Thailand

Bumrungrad International Hospital reported total revenue of THB 25,449 million (~USD 720 million) in FY2025, per its SET Annual Report, with healthcare revenue comprising 98.8% of the total. The hospital treated over 604,000 international medical episodes from more than 180 countries in 2025, with top revenue contributors from Qatar, Myanmar, and the United States. Bumrungrad's 580 licensed beds and premium positioning command gross margins of 51.2% and operating margins of 35.0%, among the highest in global hospital operations. The company's strategic differentiation lies in its 'one-stop' international patient model: dedicated concierge services, visa assistance, interpreter support in 30+ languages, and direct billing agreements with 250+ international insurers.

3. Asklepios Kliniken | Private (KGaA) | Hamburg, Germany

Asklepios Kliniken reported consolidated revenue of EUR 6,401.2 million in FY2025, per its IFRS Annual Report, with 86.8% generated in acute care hospitals and 12.2% in rehabilitation clinics. The group treated 3,899,121 patients across approximately 160 healthcare facilities in 2025, including 800,423 inpatient cases and 3,098,698 outpatient cases --- confirming the structural trend toward outpatientization.

Asklepios's strategic position in medical tourism is anchored in its role as a destination for European cross-border patients seeking timely access to specialized procedures unavailable or delayed in their home systems, particularly from the UK and EU member states with long NHS waiting lists. The group's 30.5% equity ratio and 2.8x net debt-to-EBITDA provide financial resilience to absorb Germany's hospital reform pressures while maintaining international patient service quality.

4. Apollo Hospitals | NSE: APOLLOHOSP | Chennai, India

Apollo Hospitals reported consolidated net sales of INR 217,940 million (~USD 2.6 billion) in FY2025, with operating profit growing 26.7% year-over-year and net profit surging 61.0% YoY, per NSE filings. The group operates over 70 hospitals with 70%+ occupancy in international patient wards across major Indian cities, and reported 3,600+ robotic surgeries and 110,000+ chemotherapy cycles in FY2024.

Apollo's strategic moat is built on clinical depth: it is one of the few hospital networks globally capable of offering quaternary care --- including complex organ transplants, precision oncology, and advanced robotic surgery --- at cost levels 60–70% below U.S. benchmarks. In August 2025, Apollo Health City Hyderabad received the 'International Medical Tourism Award' for Excellence in Customer Service from the International Medical Travel Journal, UK --- the only Indian hospital so honored --- validating its patient experience infrastructure.

5. Fortis Healthcare | NSE: FORTIS | Gurugram, India

Fortis Healthcare reported revenue from operations of INR 7,783 crores (~USD 930 million) in FY2025, with EBITDA of INR 1,655 crores and reported PAT of INR 809 crores, per its NSE Annual Report. The company operates 27+ hospitals across India with 69% overall occupancy and 39.2 million tests performed annually by its Agilus diagnostics subsidiary. Fortis has expanded advanced surgical programs and international patient care units, reporting a 15–18% increase in international patient inflow driven by collaborative care models and telemedicine integration.

In September 2025, Fortis launched a 200-bed multispecialty hospital in Greater Noida, strategically located near the upcoming Jewar International Airport --- a proximity play designed to capture Delhi-NCR's growing inbound medical tourism flow. In June 2025, Fortis was honored with the Medical Value Travel Award 2025 at Advantage Healthcare India, reinforcing its brand credibility in the global medical tourism corridor.

6. Medanta (Global Health) | NSE: MEDANTA | Gurugram, India

Medanta --- operating under the Global Health corporate entity --- reported trailing-twelve-month revenue of INR 44,103 million (~USD 530 million) as of March 2026, with net profit of INR 5,565 million and a 12.6% net profit margin, per NSE filings. The group's flagship Medanta -- The Medicity in Gurugram is a 1,600+ bed quaternary care facility specializing in organ transplants, cardiac surgery, and oncology --- clinical domains that command the highest international patient premiums.

Medanta's strategic differentiation lies in its 'high-complexity, high-margin' positioning: rather than competing on volume for routine procedures, it targets the most complex cases that justify premium pricing even within India's cost-competitive market. The group's international patient referral network spans the Middle East, Africa, and Central Asia, with dedicated international patient coordinators and direct-pay packages that bypass insurance complexity for cash-paying foreign patients.

7. Raffles Medical Group | SGX: BSL | Singapore

Raffles Medical Group reported revenue of SGD 765.3 million (~USD 570 million) in FY2025, with Profit After Tax and Minority Interests of SGD 70.6 million, per its SGX Annual Report. The group's Hospital Services division generated SGD 357.8 million (+3.5% YoY), while Healthcare Services contributed SGD 285.9 million, and Raffles Health Insurance grew 4.1% to SGD 185.2 million.

Raffles operates an integrated healthcare ecosystem across 14 Asian cities including Singapore, China, Japan, Vietnam, and Cambodia --- spanning hospitals, primary care, dental, transitional care, and insurance. In 2025, the group opened its second medical centre in Japan (Hakata, Fukuoka) and scheduled the RafflesHealthyLongevityCentre for Q1 2026 --- a physician-led, multidisciplinary preventive care facility targeting high-net-worth medical tourists seeking longevity and wellness services.

8. Samitivej Hospital (BDMS Group) | Bangkok, Thailand

Samitivej Hospital operates as a subsidiary of BDMS, specializing in pediatric and women's health services with a strong international patient focus. In March 2025, Samitivej Srinakarin Hospital opened a new Samitivej International Children's Hospital building comprising 103 beds --- a capacity expansion directly targeting the Gulf region's demand for pediatric subspecialty care.

Samitivej's strategic positioning within BDMS allows it to leverage the group's international patient referral network, insurance partnerships, and digital health infrastructure while maintaining a distinct brand identity in family-centered care. The hospital's focus on pediatric cardiac surgery, neonatal intensive care, and pediatric oncology attracts patients from Myanmar, Cambodia, Laos, Vietnam, and the Middle East --- corridors where local pediatric subspecialty capacity is limited.

9. Bangkok Chain Hospital (BCH) | SET: BCH | Bangkok, Thailand

Bangkok Chain Hospital is a mid-tier public hospital group listed on the SET, serving both cash-paying patients and Social Security Office (SSO) scheme members. The group received a large SSO quota of 314,000 in 2024, leading to approximately 100,000 registered members for BCH over 2024–2026.

BCH's strategic positioning is distinct from premium competitors like Bumrungrad and BDMS: it targets the mid-market segment of medical tourists who seek quality care at lower price points than flagship international hospitals, particularly from CLMV countries (Cambodia, Laos, Myanmar, Vietnam). The group's well-balanced foreign and SSO patient revenue mix provides stability against fluctuations in international demand, while its superior EBITDA margin versus mid-to-small hospital peers reflects operational discipline.

10. KPJ Healthcare Berhad | Bursa Malaysia: KPJ | Kuala Lumpur, Malaysia

KPJ Healthcare is Malaysia's largest private hospital network, listed on Bursa Malaysia, with operations spanning Malaysia, Indonesia, Thailand, and Bangladesh. The group's strategic positioning in medical tourism is anchored in Malaysia's halal-friendly healthcare ecosystem --- a unique value proposition for Muslim patients from the Middle East, Indonesia, and South Asia who seek culturally compatible care.

Malaysia attracted over 1.22 million medical tourists in 2019, and KPJ's network of 20+ hospitals captures a significant share of this inbound flow, particularly for cardiac surgery, orthopaedics, and fertility treatments. KPJ's government-backed partnerships with the Malaysia Healthcare Travel Council (MHTC) provide marketing support and visa facilitation that individual hospitals cannot match, creating a national-brand advantage for Malaysian medical tourism.

M&A Activity Tracker (2021–2025)

The Medical Tourism Market has experienced targeted consolidation as hospital groups pursued inorganic growth to capture the converging wellness, therapeutic, and digital health segments. Market Research Future tracks the following verified, named transactions directly relevant to the medical tourism market.

Key Trend: MRFR analysis identifies geographic corridor expansion and wellness-therapeutic integration as the dominant strategic themes in medical tourism. BDMS's multi-hospital network expansion across Thailand and Fortis's airport-proximity play demonstrate that medical tourism is evolving from single-destination 'hospital + hotel' models into integrated regional ecosystems.

R&D Investment & Innovation Signals

• BDMS opened four new hospitals in 2025 --- Samitivej International Children's Hospital (103 beds), Bangkok Hospital Chiangmai (90 beds), Phyathai Bowin Hospital (59 beds), and Bangkok Hospital Khao Yai (28 beds) --- representing the most aggressive capacity expansion in Thai private healthcare history, directly aligned with post-pandemic tourism recovery and medical tourism corridor development.

• Bumrungrad treated over 604,000 international medical episodes from 180+ countries in 2025, with Qatar (+36% YoY), Myanmar (+31% YoY), and American (+19% YoY) patients driving growth --- a patient mix diversification that reduces dependence on any single source market and validates its multi-language concierge model.

• Apollo Hospitals received the International Medical Tourism Award for Excellence in Customer Service in August 2025 --- the only Indian hospital honored --- reinforcing its brand credibility and signaling that Indian medical tourism is competing on service quality, not just cost arbitrage.

• Fortis Healthcare launched a 200-bed multispecialty hospital in Greater Noida in September 2025, strategically positioned near the upcoming Jewar International Airport --- a corridor-focused investment designed to capture incremental international patient flow from Delhi-NCR's expanding aviation connectivity.

• Raffles Medical Group opened its second Japanese medical centre in Hakata, Fukuoka in June 2024 and scheduled the RafflesHealthyLongevityCentre for Q1 2026 --- a strategic pivot toward preventive, longevity-focused medical tourism that targets high-net-worth patients seeking personalized health optimization rather than acute intervention.

• Asklepios Kliniken treated 3.9 million patients across 160 facilities in 2025, with outpatient cases growing 7.2% YoY --- confirming the structural shift toward outpatientization that reduces per-case costs and aligns with medical tourism patients' preference for shorter hospital stays and faster recovery.

• Medanta's 12.6% net profit margin and quaternary care focus (organ transplants, cardiac surgery, oncology) demonstrate that high-complexity, high-margin procedures can sustain profitability even within India's cost-competitive market --- a model that attracts premium international patients from the Middle East and Africa.

• By 2030, MRFR projects that AI-driven patient matching platforms, telemedicine pre-consultation, and remote post-operative monitoring will compress the medical tourism decision cycle from 60–90 days to 14–21 days --- a shift that will favor hospital groups with integrated digital health infrastructure over standalone facilities dependent on traditional facilitator networks.